Report Detail
Global Proto-Oncogene Drgu Market Insights, Forecast to 2025
- RnM2873411 |
- 04 February, 2019 |
- Global |
- 111 Pages |
- QYResearch |
- Pharma & Healthcare
The global Proto-Oncogene Drgu market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Proto-Oncogene Drgu market based on company, product type, end user and key regions.
This report studies the global market size of Proto-Oncogene Drgu in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Proto-Oncogene Drgu in these regions.
This research report categorizes the global Proto-Oncogene Drgu market by top players/brands, region, type and end user. This report also studies the global Proto-Oncogene Drgu market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
ARIAD Pharmaceuticals
AstraZeneca
Bayer Healthcare
Bristol-Myers Squibb
ChemGenex Pharmaceuticals
Dexa Medica
Eisai Pharmaceuticals
Exelixis
GlaxoSmithKline
Novartis
Onyx Pharmaceuticals
Plexxikon
Pfizer
Market size by Product
Axitinib (Inlyta)
Ponatinib (Iclusig)
Imatinib (Gleevec)
Sunitinib (Sutent)
Pazopanib (Votrient)
Dabrafenib (Tafinlar)
Vandetanib (Caprelsa)
Vemurafenib (Zelboraf)
Cabozantinib (Cabometyx and Cometriq)
Sorafenib (Nexavar)
Market size by End User
Clinic
Hospital
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Proto-Oncogene Drgu market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Proto-Oncogene Drgu market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Proto-Oncogene Drgu companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Proto-Oncogene Drgu submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Proto-Oncogene Drgu are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Proto-Oncogene Drgu market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Proto-Oncogene Drgu Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Proto-Oncogene Drgu Market Size Growth Rate by Product
- 1.4.2 Axitinib (Inlyta)
- 1.4.3 Ponatinib (Iclusig)
- 1.4.4 Imatinib (Gleevec)
- 1.4.5 Sunitinib (Sutent)
- 1.4.6 Pazopanib (Votrient)
- 1.4.7 Dabrafenib (Tafinlar)
- 1.4.8 Vandetanib (Caprelsa)
- 1.4.9 Vemurafenib (Zelboraf)
- 1.4.10 Cabozantinib (Cabometyx and Cometriq)
- 1.4.11 Sorafenib (Nexavar)
- 1.5 Market by End User
- 1.5.1 Global Proto-Oncogene Drgu Market Size Growth Rate by End User
- 1.5.2 Clinic
- 1.5.3 Hospital
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Proto-Oncogene Drgu Market Size
- 2.1.1 Global Proto-Oncogene Drgu Revenue 2014-2025
- 2.1.2 Global Proto-Oncogene Drgu Sales 2014-2025
- 2.2 Proto-Oncogene Drgu Growth Rate by Regions
- 2.2.1 Global Proto-Oncogene Drgu Sales by Regions
- 2.2.2 Global Proto-Oncogene Drgu Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Proto-Oncogene Drgu Sales by Manufacturers
- 3.1.1 Proto-Oncogene Drgu Sales by Manufacturers
- 3.1.2 Proto-Oncogene Drgu Sales Market Share by Manufacturers
- 3.1.3 Global Proto-Oncogene Drgu Market Concentration Ratio (CR5 and HHI)
- 3.2 Proto-Oncogene Drgu Revenue by Manufacturers
- 3.2.1 Proto-Oncogene Drgu Revenue by Manufacturers (2014-2019)
- 3.2.2 Proto-Oncogene Drgu Revenue Share by Manufacturers (2014-2019)
- 3.3 Proto-Oncogene Drgu Price by Manufacturers
- 3.4 Proto-Oncogene Drgu Manufacturing Base Distribution, Product Types
- 3.4.1 Proto-Oncogene Drgu Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Proto-Oncogene Drgu Product Type
- 3.4.3 Date of International Manufacturers Enter into Proto-Oncogene Drgu Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Proto-Oncogene Drgu Sales by Product
- 4.2 Global Proto-Oncogene Drgu Revenue by Product
- 4.3 Proto-Oncogene Drgu Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Proto-Oncogene Drgu Breakdown Data by End User
6 North America
- 6.1 North America Proto-Oncogene Drgu by Countries
- 6.1.1 North America Proto-Oncogene Drgu Sales by Countries
- 6.1.2 North America Proto-Oncogene Drgu Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Proto-Oncogene Drgu by Product
- 6.3 North America Proto-Oncogene Drgu by End User
7 Europe
- 7.1 Europe Proto-Oncogene Drgu by Countries
- 7.1.1 Europe Proto-Oncogene Drgu Sales by Countries
- 7.1.2 Europe Proto-Oncogene Drgu Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Proto-Oncogene Drgu by Product
- 7.3 Europe Proto-Oncogene Drgu by End User
8 Asia Pacific
- 8.1 Asia Pacific Proto-Oncogene Drgu by Countries
- 8.1.1 Asia Pacific Proto-Oncogene Drgu Sales by Countries
- 8.1.2 Asia Pacific Proto-Oncogene Drgu Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Proto-Oncogene Drgu by Product
- 8.3 Asia Pacific Proto-Oncogene Drgu by End User
9 Central & South America
- 9.1 Central & South America Proto-Oncogene Drgu by Countries
- 9.1.1 Central & South America Proto-Oncogene Drgu Sales by Countries
- 9.1.2 Central & South America Proto-Oncogene Drgu Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Proto-Oncogene Drgu by Product
- 9.3 Central & South America Proto-Oncogene Drgu by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Proto-Oncogene Drgu by Countries
- 10.1.1 Middle East and Africa Proto-Oncogene Drgu Sales by Countries
- 10.1.2 Middle East and Africa Proto-Oncogene Drgu Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Proto-Oncogene Drgu by Product
- 10.3 Middle East and Africa Proto-Oncogene Drgu by End User
11 Company Profiles
- 11.1 ARIAD Pharmaceuticals
- 11.1.1 ARIAD Pharmaceuticals Company Details
- 11.1.2 Company Business Overview
- 11.1.3 ARIAD Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 ARIAD Pharmaceuticals Proto-Oncogene Drgu Products Offered
- 11.1.5 ARIAD Pharmaceuticals Recent Development
- 11.2 AstraZeneca
- 11.2.1 AstraZeneca Company Details
- 11.2.2 Company Business Overview
- 11.2.3 AstraZeneca Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 AstraZeneca Proto-Oncogene Drgu Products Offered
- 11.2.5 AstraZeneca Recent Development
- 11.3 Bayer Healthcare
- 11.3.1 Bayer Healthcare Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Bayer Healthcare Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Bayer Healthcare Proto-Oncogene Drgu Products Offered
- 11.3.5 Bayer Healthcare Recent Development
- 11.4 Bristol-Myers Squibb
- 11.4.1 Bristol-Myers Squibb Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Bristol-Myers Squibb Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Bristol-Myers Squibb Proto-Oncogene Drgu Products Offered
- 11.4.5 Bristol-Myers Squibb Recent Development
- 11.5 ChemGenex Pharmaceuticals
- 11.5.1 ChemGenex Pharmaceuticals Company Details
- 11.5.2 Company Business Overview
- 11.5.3 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Products Offered
- 11.5.5 ChemGenex Pharmaceuticals Recent Development
- 11.6 Dexa Medica
- 11.6.1 Dexa Medica Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Dexa Medica Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Dexa Medica Proto-Oncogene Drgu Products Offered
- 11.6.5 Dexa Medica Recent Development
- 11.7 Eisai Pharmaceuticals
- 11.7.1 Eisai Pharmaceuticals Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Eisai Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Eisai Pharmaceuticals Proto-Oncogene Drgu Products Offered
- 11.7.5 Eisai Pharmaceuticals Recent Development
- 11.8 Exelixis
- 11.8.1 Exelixis Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Exelixis Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Exelixis Proto-Oncogene Drgu Products Offered
- 11.8.5 Exelixis Recent Development
- 11.9 GlaxoSmithKline
- 11.9.1 GlaxoSmithKline Company Details
- 11.9.2 Company Business Overview
- 11.9.3 GlaxoSmithKline Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 GlaxoSmithKline Proto-Oncogene Drgu Products Offered
- 11.9.5 GlaxoSmithKline Recent Development
- 11.10 Novartis
- 11.10.1 Novartis Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Novartis Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Novartis Proto-Oncogene Drgu Products Offered
- 11.10.5 Novartis Recent Development
- 11.11 Onyx Pharmaceuticals
- 11.12 Plexxikon
- 11.13 Pfizer
12 Future Forecast
- 12.1 Proto-Oncogene Drgu Market Forecast by Regions
- 12.1.1 Global Proto-Oncogene Drgu Sales Forecast by Regions 2019-2025
- 12.1.2 Global Proto-Oncogene Drgu Revenue Forecast by Regions 2019-2025
- 12.2 Proto-Oncogene Drgu Market Forecast by Product
- 12.2.1 Global Proto-Oncogene Drgu Sales Forecast by Product 2019-2025
- 12.2.2 Global Proto-Oncogene Drgu Revenue Forecast by Product 2019-2025
- 12.3 Proto-Oncogene Drgu Market Forecast by End User
- 12.4 North America Proto-Oncogene Drgu Forecast
- 12.5 Europe Proto-Oncogene Drgu Forecast
- 12.6 Asia Pacific Proto-Oncogene Drgu Forecast
- 12.7 Central & South America Proto-Oncogene Drgu Forecast
- 12.8 Middle East and Africa Proto-Oncogene Drgu Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Proto-Oncogene Drgu Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Proto-Oncogene Drgu . Industry analysis & Market Report on Proto-Oncogene Drgu is a syndicated market report, published as Global Proto-Oncogene Drgu Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Proto-Oncogene Drgu market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
